Advances in Metered Dose Inhaler Technology: Hardware Development

被引:76
作者
Stein, Stephen W. [1 ]
Sheth, Poonam [2 ]
Hodson, P. David [3 ]
Myrdal, Paul B. [2 ]
机构
[1] 3M Co, 3M Drug Delivery Syst, St Paul, MN 55144 USA
[2] Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA
[3] 3M Healthcare Ltd, Loughborough LE11 5RE, Leics, England
关键词
actuator; add-on devices; canister; dose counters; metering valve; AERODYNAMIC PARTICLE-SIZE; DRUG-DELIVERY; PRESSURIZED AEROSOL; HYDROFLUOROALKANE; COUNTER; DESIGN; ASTHMA; BECLOMETHASONE; PRESERVATIVES; ATOMIZATION;
D O I
10.1208/s12249-013-0062-y
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pressurized metered dose inhalers (MDIs) were first introduced in the 1950s and they are currently widely prescribed as portable systems to treat pulmonary conditions. MDIs consist of a formulation containing dissolved or suspended drug and hardware needed to contain the formulation and enable efficient and consistent dose delivery to the patient. The device hardware includes a canister that is appropriately sized to contain sufficient formulation for the required number of doses, a metering valve capable of delivering a consistent amount of drug with each dose delivered, an actuator mouthpiece that atomizes the formulation and serves as a conduit to deliver the aerosol to the patient, and often an indicating mechanism that provides information to the patient on the number of doses remaining. This review focuses on the current state-of-the-art of MDI hardware and includes discussion of enhancements made to the device's core subsystems. In addition, technologies that aid the correct use of MDIs will be discussed. These include spacers, valved holding chambers, and breath-actuated devices. Many of the improvements discussed in this article increase the ability of MDI systems to meet regulatory specifications. Innovations that enhance the functionality of MDIs continue to be balanced by the fact that a key advantage of MDI systems is their low cost per dose. The expansion of the health care market in developing countries and the increased focus on health care costs in many developed countries will ensure that MDIs remain a cost-effective crucial delivery system for treating pulmonary conditions for many years to come.
引用
收藏
页码:326 / 338
页数:13
相关论文
共 113 条
[1]  
Alston W, 2004, World Intellectual Property Organization patent, Patent No. [WO 2004/041340, 2004041340]
[2]  
[Anonymous], 2000, RESP DRUG DELIV
[3]  
Armer TA, 2000, United States patent, Patent No. [US 6,095,141, 6095141]
[4]  
ASHURST IC, 2000, Patent No. 6131566
[5]  
Bacon RJ, 2002, RESP DRUG DELIV, V2, P403
[6]   THE EFFECT OF DELAY, MULTIPLE ACTUATIONS AND SPACER STATIC CHARGE ON THE IN-VITRO DELIVERY OF BUDESONIDE FROM THE NEBUHALER [J].
BARRY, PW ;
OCALLAGHAN, C .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 40 (01) :76-78
[7]   Influence of the valve lubricant on the aerodynamic particle size of a metered dose inhaler [J].
Berry, J ;
Kline, L ;
Naini, V ;
Chaudhry, S ;
Hart, J ;
Sequeira, J .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2004, 30 (03) :267-275
[8]   Influence of the metering chamber volume and actuator design on the aerodynamic particle size of a metered dose inhaler [J].
Berry, J ;
Heimbecher, S ;
Hart, JL ;
Sequeira, J .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2003, 29 (08) :865-876
[9]  
Bisgaard H, 2002, LUNG BIOL HEALTH DIS, V162, P389
[10]  
Blower AW, 1997, United States patent, Patent No. [US 5,682,875, 5682875]